Drugs / Allogeneic CD19 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05164042 | Feb 2021 → Feb 2024 | acute lymphoblastic leukemia | Shenzhen University General Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05164042 ↗ |
| Action | Deplete | “Chimeric antigen receptor (CAR) T cells enable T cells to recognize and kill tumor cells that express specific antigens” NCT05164042 ↗ |
| Modality | Cell therapy | “Allogeneic CD19 CAR-T cells” NCT05164042 ↗ |
| Route | Intravenous | “receive intravenous infusion of allogeneic CD19 CAR-T cells” NCT05164042 ↗ |